KISUNLA 350mg concentrate for solution for infusion ELI LILLY ORIGINAL MEDICINE
Chemical substance: donanemab
ATC code: N06DX05 • Nervous system | Anti-dementia drugs | Other anti-dementia drugs
Active substance
Results for the substance donanemab
1 result
About this active substance
Donanemab is a medicine for adults with early symptomatic Alzheimer’s disease, meaning mild cognitive impairment or mild dementia caused by Alzheimer’s disease. It is a monoclonal antibody that attaches to beta-amyloid plaques in the brain and helps clear them. The aim is to slow worsening of memory, thinking and daily functioning, not to cure the disease.
It is given as an intravenous infusion in a healthcare setting, on a schedule set by a specialist team. Before treatment, doctors confirm amyloid disease and assess whether the stage is suitable, including brain MRI scans. ApoE ε4 genetic testing may be recommended because it helps estimate the risk of some brain-related side effects.
The main safety concern is amyloid-related imaging abnormalities, known as ARIA. ARIA may involve brain swelling or small areas of bleeding. It may cause no symptoms, but it can cause headache, confusion, dizziness, vision changes, nausea, seizures or sudden worsening. Infusion reactions can also occur, such as fever, chills, rash, itching or shortness of breath.
Donanemab is not suitable for everyone, especially with high bleeding risk, anticoagulant treatment, uncontrolled high blood pressure, certain MRI findings or inability to have MRI monitoring. Patients and caregivers should keep the patient card available and report any new neurological symptoms immediately. Regular monitoring helps decide whether treatment can safely continue.
It is given as an intravenous infusion in a healthcare setting, on a schedule set by a specialist team. Before treatment, doctors confirm amyloid disease and assess whether the stage is suitable, including brain MRI scans. ApoE ε4 genetic testing may be recommended because it helps estimate the risk of some brain-related side effects.
The main safety concern is amyloid-related imaging abnormalities, known as ARIA. ARIA may involve brain swelling or small areas of bleeding. It may cause no symptoms, but it can cause headache, confusion, dizziness, vision changes, nausea, seizures or sudden worsening. Infusion reactions can also occur, such as fever, chills, rash, itching or shortness of breath.
Donanemab is not suitable for everyone, especially with high bleeding risk, anticoagulant treatment, uncontrolled high blood pressure, certain MRI findings or inability to have MRI monitoring. Patients and caregivers should keep the patient card available and report any new neurological symptoms immediately. Regular monitoring helps decide whether treatment can safely continue.